# A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

Source: https://onco.cc/trials/nct06679036/  
OnCo record `nct06679036` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HRS-8080 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.

## Summary

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients is a phase 1/2 interventional study registered as NCT06679036 by Shandong Suncadia Medicine Co., Ltd., with 300 participants planned, started 2025-01-21 and due to reach its primary completion in 2026-10-30. Interventions recorded: HRS-2189, Fluvustat, HRS-8080, HRS-6209 and HRS-1358.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06679036
- Phase: 1/2
- Setting: An Open, Multicenter Phase Ib/II Clinical Study on the Safety, Tolerance, Pharmacokinetics, and Initial Efficacy of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Patients With Advanced Unresectable or Metastatic Breast Cancer
- Sponsor: Shandong Suncadia Medicine Co., Ltd.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06679036: https://clinicaltrials.gov/study/NCT06679036

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [HRS-8080](https://onco.cc/drugs/hrs-8080/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06679036.json